ParkinsonFranceV1, Main, Exploration, bibRecord, 001D45

Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons

Identifieur interne : 001D45 ( Main/Exploration ); précédent : 001D44; suivant : 001D46

Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons

Auteurs : Ouafa Arib [France] ; Pascal Rat [France] ; Robert Molimard [France] ; Abderrahman Chait [Maroc] ; Philippe Faure [France] ; Renaud De Beaurepaire [France]

Source :

European journal of pharmacology [ 0014-2999 ] ; 2010.

RBID : Pascal:10-0152691

Descripteurs français

Pascal (Inist)
- Electrophysiologie, Caractérisation, Neurone dopaminergique, Nicotine, Amine oxidase (flavin-containing), Sélégiline, Béfloxatone, Maladie de Parkinson, Psychose, Tabagisme, Antiparkinsonien, Psychotrope, Antidépresseur, Harmane dérivé, β-Carboline dérivé.
Wicri :
- topic : Tabagisme.

English descriptors

KwdEn :
- Amine oxidase (flavin-containing), Antidepressant agent, Antiparkinson agent, Befloxatone, Characterization, Dopaminergic neuron, Electrophysiology, Nicotine, Parkinson disease, Psychosis, Psychotropic, Selegiline, Tobacco smoking.

Abstract

It has been suggested that the beta-carbolines harmane and norharmane may be involved in the pathophysiology of Parkinson's disease, psychosis and addiction, but the mechanisms of these possible effects remain to be elucidated. In the present study, the effects of the two compounds were examined by using in vivo extracellular recordings of ventral tegmental dopamine neurons. The effects of harmane (2 mg/kg) and norharmane (2 mg/kg), were compared to those of nicotine (11 μg/kg), of cotinine (0.5 mg/kg), of the monoamine-oxidase-A inhibitor befloxatone (0.12 mg/kg), and of the monoamine-oxidase-B inhibitor selegiline (0.5 mg/kg). The effects of harmane were also tested after pre-treatment with the nicotine receptor antagonist mecamylamine. The results show that all substances, except befloxatone, activate the firing and/or burst activity of dopamine neurons. The increase in firing rate produced by harmane was approximately 18 times greater than that produced by nicotine. Such powerful excitation of dopamine neurons by harmane may in part explain its involvement in neurotoxicity, psychosis and addiction. The absence of effect of befloxatone supports the hypothesis that the effect of harmane is not related to its monoamine-oxidase-A inhibitory properties. Mecamylamine inhibited by approximately 80% the activity of harmane, indicating that the activating effect of harmane on dopamine neurons involves several mechanisms, among which activation of nicotinic receptors likely has a prominent importance. The results of the present study support the hypothesis that harmane could be a tobacco (or smoke) component other than nicotine involved in tobacco dependence.

Url:

https://hal.archives-ouvertes.fr/hal-00465520

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons</title>
<author><name sortKey="Arib, Ouafa" sort="Arib, Ouafa" uniqKey="Arib O" first="Ouafa" last="Arib">Ouafa Arib</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratoire de Psychopharmacologie, Centre Hospitalier Paul Guiraud, 54 avenue de la Republique</s1>
<s2>94806 Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur</s1>
<s2>75724 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rat, Pascal" sort="Rat, Pascal" uniqKey="Rat P" first="Pascal" last="Rat">Pascal Rat</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratoire de Psychopharmacologie, Centre Hospitalier Paul Guiraud, 54 avenue de la Republique</s1>
<s2>94806 Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Molimard, Robert" sort="Molimard, Robert" uniqKey="Molimard R" first="Robert" last="Molimard">Robert Molimard</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratoire de Psychopharmacologie, Centre Hospitalier Paul Guiraud, 54 avenue de la Republique</s1>
<s2>94806 Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chait, Abderrahman" sort="Chait, Abderrahman" uniqKey="Chait A" first="Abderrahman" last="Chait">Abderrahman Chait</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Département de Biologie, Faculté Semlalia, Universit Cadi Ayyad</s1>
<s2>40 000 Marrakech</s2>
<s3>MAR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Maroc</country>
<wicri:noRegion>40 000 Marrakech</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Faure, Philippe" sort="Faure, Philippe" uniqKey="Faure P" first="Philippe" last="Faure">Philippe Faure</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur</s1>
<s2>75724 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Beaurepaire, Renaud" sort="De Beaurepaire, Renaud" uniqKey="De Beaurepaire R" first="Renaud" last="De Beaurepaire">Renaud De Beaurepaire</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratoire de Psychopharmacologie, Centre Hospitalier Paul Guiraud, 54 avenue de la Republique</s1>
<s2>94806 Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0152691</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0152691 INIST</idno>
<idno type="RBID">Pascal:10-0152691</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000597</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000D60</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000496</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000496</idno>
<idno type="wicri:doubleKey">0014-2999:2010:Arib O:electrophysiological:characterization:of</idno>
<idno type="wicri:Area/Main/Merge">001E83</idno>
<idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:hal-00465520</idno>
<idno type="url">https://hal.archives-ouvertes.fr/hal-00465520</idno>
<idno type="wicri:Area/Hal/Corpus">000383</idno>
<idno type="wicri:Area/Hal/Curation">000383</idno>
<idno type="wicri:Area/Hal/Checkpoint">000706</idno>
<idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000706</idno>
<idno type="wicri:doubleKey">0014-2999:2010:Arib O:electrophysiological:characterization:of</idno>
<idno type="wicri:Area/Main/Merge">001A31</idno>
<idno type="wicri:Area/Main/Curation">001D45</idno>
<idno type="wicri:Area/Main/Exploration">001D45</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons</title>
<author><name sortKey="Arib, Ouafa" sort="Arib, Ouafa" uniqKey="Arib O" first="Ouafa" last="Arib">Ouafa Arib</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratoire de Psychopharmacologie, Centre Hospitalier Paul Guiraud, 54 avenue de la Republique</s1>
<s2>94806 Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur</s1>
<s2>75724 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rat, Pascal" sort="Rat, Pascal" uniqKey="Rat P" first="Pascal" last="Rat">Pascal Rat</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratoire de Psychopharmacologie, Centre Hospitalier Paul Guiraud, 54 avenue de la Republique</s1>
<s2>94806 Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Molimard, Robert" sort="Molimard, Robert" uniqKey="Molimard R" first="Robert" last="Molimard">Robert Molimard</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratoire de Psychopharmacologie, Centre Hospitalier Paul Guiraud, 54 avenue de la Republique</s1>
<s2>94806 Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chait, Abderrahman" sort="Chait, Abderrahman" uniqKey="Chait A" first="Abderrahman" last="Chait">Abderrahman Chait</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Département de Biologie, Faculté Semlalia, Universit Cadi Ayyad</s1>
<s2>40 000 Marrakech</s2>
<s3>MAR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Maroc</country>
<wicri:noRegion>40 000 Marrakech</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Faure, Philippe" sort="Faure, Philippe" uniqKey="Faure P" first="Philippe" last="Faure">Philippe Faure</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur</s1>
<s2>75724 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="De Beaurepaire, Renaud" sort="De Beaurepaire, Renaud" uniqKey="De Beaurepaire R" first="Renaud" last="De Beaurepaire">Renaud De Beaurepaire</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratoire de Psychopharmacologie, Centre Hospitalier Paul Guiraud, 54 avenue de la Republique</s1>
<s2>94806 Villejuif</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Villejuif</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European journal of pharmacology</title>
<title level="j" type="abbreviated">Eur. j. pharmacol.</title>
<idno type="ISSN">0014-2999</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European journal of pharmacology</title>
<title level="j" type="abbreviated">Eur. j. pharmacol.</title>
<idno type="ISSN">0014-2999</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amine oxidase (flavin-containing)</term>
<term>Antidepressant agent</term>
<term>Antiparkinson agent</term>
<term>Befloxatone</term>
<term>Characterization</term>
<term>Dopaminergic neuron</term>
<term>Electrophysiology</term>
<term>Nicotine</term>
<term>Parkinson disease</term>
<term>Psychosis</term>
<term>Psychotropic</term>
<term>Selegiline</term>
<term>Tobacco smoking</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Electrophysiologie</term>
<term>Caractérisation</term>
<term>Neurone dopaminergique</term>
<term>Nicotine</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Sélégiline</term>
<term>Béfloxatone</term>
<term>Maladie de Parkinson</term>
<term>Psychose</term>
<term>Tabagisme</term>
<term>Antiparkinsonien</term>
<term>Psychotrope</term>
<term>Antidépresseur</term>
<term>Harmane dérivé</term>
<term>β-Carboline dérivé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Tabagisme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">It has been suggested that the beta-carbolines harmane and norharmane may be involved in the pathophysiology of Parkinson's disease, psychosis and addiction, but the mechanisms of these possible effects remain to be elucidated. In the present study, the effects of the two compounds were examined by using in vivo extracellular recordings of ventral tegmental dopamine neurons. The effects of harmane (2 mg/kg) and norharmane (2 mg/kg), were compared to those of nicotine (11 μg/kg), of cotinine (0.5 mg/kg), of the monoamine-oxidase-A inhibitor befloxatone (0.12 mg/kg), and of the monoamine-oxidase-B inhibitor selegiline (0.5 mg/kg). The effects of harmane were also tested after pre-treatment with the nicotine receptor antagonist mecamylamine. The results show that all substances, except befloxatone, activate the firing and/or burst activity of dopamine neurons. The increase in firing rate produced by harmane was approximately 18 times greater than that produced by nicotine. Such powerful excitation of dopamine neurons by harmane may in part explain its involvement in neurotoxicity, psychosis and addiction. The absence of effect of befloxatone supports the hypothesis that the effect of harmane is not related to its monoamine-oxidase-A inhibitory properties. Mecamylamine inhibited by approximately 80% the activity of harmane, indicating that the activating effect of harmane on dopamine neurons involves several mechanisms, among which activation of nicotinic receptors likely has a prominent importance. The results of the present study support the hypothesis that harmane could be a tobacco (or smoke) component other than nicotine involved in tobacco dependence.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>Maroc</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
<li>Villejuif</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Arib, Ouafa" sort="Arib, Ouafa" uniqKey="Arib O" first="Ouafa" last="Arib">Ouafa Arib</name>
</region>
<name sortKey="Arib, Ouafa" sort="Arib, Ouafa" uniqKey="Arib O" first="Ouafa" last="Arib">Ouafa Arib</name>
<name sortKey="De Beaurepaire, Renaud" sort="De Beaurepaire, Renaud" uniqKey="De Beaurepaire R" first="Renaud" last="De Beaurepaire">Renaud De Beaurepaire</name>
<name sortKey="Faure, Philippe" sort="Faure, Philippe" uniqKey="Faure P" first="Philippe" last="Faure">Philippe Faure</name>
<name sortKey="Molimard, Robert" sort="Molimard, Robert" uniqKey="Molimard R" first="Robert" last="Molimard">Robert Molimard</name>
<name sortKey="Rat, Pascal" sort="Rat, Pascal" uniqKey="Rat P" first="Pascal" last="Rat">Pascal Rat</name>
</country>
<country name="Maroc"><noRegion><name sortKey="Chait, Abderrahman" sort="Chait, Abderrahman" uniqKey="Chait A" first="Abderrahman" last="Chait">Abderrahman Chait</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D45 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D45 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:10-0152691
   |texte=   Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

La maladie de Parkinson en France (serveur d'exploration)

Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons

Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.